# Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran)

> **NCT06613984** · — · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 660 (estimated)

## Conditions studied

- COVID-19 Vaccination

## Interventions

- **BIOLOGICAL:** Bretovameran

## Key facts

- **NCT ID:** NCT06613984
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-11
- **Primary completion:** 2026-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 660 (ESTIMATED)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06613984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06613984, "Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06613984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*